Howard Liang

In a report issued Monday, Leerink upgraded its rating of InterMune (NASDAQ: ITMN) from Market Perform to Outperform with a target price of $41. Howard Liang of Leerink anticipates that recent developments in trials done by InterMune should provide the company with plenty of upside. Esbriet...

Several analysts commented on Merck's (NYSE: MRK)'s advances on Hepatitis C cure regiment. ISI analyst Mark Schoenebaum commented that Merck's oral regimen for hepatitis C genotype 1 may be the first "truly clinical competitive" regimen against Gilead. Schoenebaum noted that this one pill per day...

Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...